drugset / Trial / NCT07413328
HWS116 Monotherapy in Patients With Advanced Solid Tumors
Phase 1
Recruiting
56 enrolled
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
NaSequentialOpen-labelTreatment
Summary
This is a Phase I open-label study that will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HWS116 monotherapy in patients with advanced solid tumors.
Timeline
- Start
- 2026-04-07
- Primary completion
- 2027-08-31
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HWS116 | Unknown | 1.5 mg/kg | Intravenous |